This instrument-dependence likely reflects an effect-size threshold/dose–response: common variants tend to produce modest downregulation of ANGPTL3, diluting downstream effects on apoB and CAD; by contrast, LoF variants cause lifelong, larger reductions that more closely mirror the biology under strong pharmacologic inhibition (67). This evidence concerns the gene ANGPTL3 and coronary artery disorder.